Humana Inc. (NYSE:HUM) is a prominent player in the health insurance industry, offering a range of health, wellness, and insurance services. The company is known for its Medicare offerings, which have been a significant part of its business model. Humana competes with other major insurers like UnitedHealth Group and Anthem in the U.S. market.
On November 25, 2025, Andrew Mok from Barclays set a price target of $234 for Humana. At that time, the stock was trading at $229.20, indicating a potential upside of approximately 2.09%. This target suggests confidence in Humana's future performance despite recent challenges.
Berman Tabacco, a national law firm, has announced an investigation into Humana regarding potential stockholder claims. The investigation focuses on allegations that Humana paid illegal kickbacks to insurance brokers. These claims were highlighted in May 2025 when the U.S. Attorney's Office for the District of Massachusetts joined a whistleblower's case.
The complaint alleges that between 2016 and 2021, Humana paid up to $250 million to Select Quote and other brokers. This was allegedly done to influence them to direct customers towards Humana's Medicare offerings. The allegations also implicate the involvement of Humana's senior officers, raising concerns about corporate governance.
Despite these allegations, Humana's stock is currently priced at $229.20, reflecting an increase of approximately 0.92% or $2.10. The stock has fluctuated between a low of $222.04 and a high of $229.82 during the trading day. Over the past year, HUM has reached a high of $315.35 and a low of $206.87, with a market capitalization of approximately $27.57 billion.
